AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03940872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-questionnaire 3PDQ
Description: Visit 1 : - The patient will have to complete the 3PDQ self-questionnaire. - The investigator will conduct an interrogation and a neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visit 2 : - The patient will have to complete the 3PDQ self-questionnaire.~- An investigator, obligatorily different from the investigator of the visit 1, will conduct to the same interrogation and the same neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visits 1 and 2 can be made on the same day. In this case the patient will fill the 3PDQ self questionnaire only once.
Study NCT02314728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.
Study NCT02314728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
Study NCT04822714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Career Competencies Intervention
Description: Mobile career competencies intervention aim to enhance the career competencies (career behavioral action) among the participants
Study NCT03949595 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT03035513 — intervention group
Intervention type: OTHER
Intervention: Continuous spikes and waves during slow sleep (CSWS)
Study NCT00542893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genasense® (G3139, oblimersen sodium)
Study NCT00542893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genasense followed by DTIC; then DTIC alone
Description: Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
Study NCT00542893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC alone; then Genasense followed by DTIC
Description: Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
Study NCT03423043 — intervention group
Intervention type: RADIATION
Intervention: Low Dose CT Scan of the Wrist
Description: A low dose CT scan will be obtained in patients with a distal radius fracture of the wrist.
Study NCT00764790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
Study NCT00764790 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Study NCT00971477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Teledermatology Care
Description: Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
Study NCT00971477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional in Office Care
Description: Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
Study NCT03041636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT03041636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study NCT02987296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunonutrition with arginine
Description: Nutritional beverage containing supplemental arginine taken 3 times per day
Study NCT02987296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Immunonutrition without Arginine
Description: Nutritional beverage without supplemental arginine taken 3 times per day
Study NCT00445471 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mifne Approach to PDD
Study NCT00445471 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Study NCT03539978 — intervention group
Intervention type: OTHER
Intervention: SM-THINk
Description: Patients will receive the SM-THINk enhanced discharge method.
Study NCT00770705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard surgical approach
Description: Historical controls
Study NCT04465799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENTREN
Description: ENTREN intervention for children (cognitive-behavioral perspective + motivational interview)
Study NCT04465799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENTREN-F
Description: ENTREN intervention for children + family intervention.
Study NCT04465799 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Behavioral modification of habits
Study NCT02143011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: orange juice
Description: intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement
Study NCT02143011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sucrose
Description: intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement
Study NCT05717894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitex Agnus Castus Extract
Description: The patient group received two pills containing 200mg of VAC daily for six months
Study NCT06043258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bond Apatite
Description: composite graft formed of biphasic calcium sulphate and hydroxyapatite at a ratio of 2:1
Study NCT06043258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss
Description: xenograft bone substitute
Study NCT03429803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAY101
Description: 28 day cycle, oral, once per week
Study NCT03637218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Study NCT03637218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study NCT03729375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10cc injection of bupivacaine
Description: 10cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
Study NCT03729375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20cc injection of bupivacaine
Description: 20cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
Study NCT04506645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5381
Description: Single dose REGN5381 administered via IV infusion
Study NCT01096953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental health care implemented by telepsychiatry
Description: Care of 6-17 year-olds with ADHD
Study NCT01096953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face care
Description: Psychiatry provided for treatment of ADHD face-to-face in office
Study NCT04506645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo matching single dose REGN 5381 administered via IV infusion
Study NCT01182441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN Device
Description: WATCHMAN Left Atrial Appendage Closure Technology
Study NCT01182441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
Study NCT04790656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Subjects will randomly placed into intervention group and control group . In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.
Study NCT04790656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer combine with CPAP
Description: Physical exercise on a cycle ergometer combine with CPAP will be performed in a single daily session from the second to the fourth postoperative days . The maximum exercise time for postoperative day 2 will be 20 min, and 30 min for the third and fourth postoperative days.
Study NCT00384774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered as intravenous infusion
Study NCT00384774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as intravenous infusion
Study NCT03079453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The patients in Group 1 were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly before tonsillectomy
Study NCT05931029 — intervention group
Intervention type: DRUG
Intervention: Idebenone
Description: The control group took Idebenone orally for 12 weeks.
Study NCT05931029 — intervention group
Intervention type: DRUG
Intervention: Naohuan Dan and Idebenone
Description: The treatment group took Naohuan Dan combined with Idebenone for treatment. Naohuan Dan is a granular preparation taken once a day, while Idebenone is a tablet taken three times a day for a total of 12 weeks.
Study NCT01891175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective caesarean section under spinal anaesthesia.
Description: Patients with scheduled caesarean.
Study NCT01891175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective caesarean section under spinal anaesthesia.
Study NCT04717453 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT02823197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transport lesson
Study NCT02823197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transport lesson and Facebook group
Study NCT03950752 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Optimized Bagel
Description: Participants will eat 132g of a bagel with an optimized composition in fatty acids in only one day, representing an ingestion of 556.5 kcal and 33g of total fat, of which 4.41g are saturated fatty acids, 24.27g are monounsaturated fatty acids, and 4.28g are polyunsaturated fatty acids.
Study NCT03950752 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Bagel
Description: Participants will eat 132g of a bagel with a conventional composition in fatty acids in only one day, representing an ingestion of 589.0 kcal and 35.6g of total fat, of which 16.76g are saturated fatty acids, 13.00g are monounsaturated fatty acids, and 5.81g are polyunsaturated fatty acids
Study NCT01345864 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Scopolamine + Donepezil Placebo + PF-04995274 Placebo
Description: Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
Study NCT01345864 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Scopolamine + Donepezil 5 mg + PF-04995274 Placebo
Description: Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 5 mg tablet orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
Study NCT01345864 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Scopolamine + Donepezil 10mg + PF-04995274 Placebo
Description: Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 10 mg (2 x 5 mg tablets) orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
Study NCT01345864 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg
Description: Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 0.25 mg oral liquid x 1 dose on Day 1
Study NCT01345864 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Description: Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 15 mg oral liquid x 1 dose on day 1
Study NCT04498637 — intervention group
Intervention type: OTHER
Intervention: 'Attitudes towards people with disability Scale'
Description: The scale 'Attitudes towards people with disability' was completed by the participants. This scale allows the analysis of the attitudes towards disability trough a score whose lower values indicate a more negative attitude and higher values indicate more positive attitudes.
Study NCT02053493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Mononitrate
Description: Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN
Study NCT02053493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo
Study NCT02084901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting biodegradable stent Orsiro implantation
Description: Drug-eluting biodegradable stent Orsiro implantation
Study NCT02084901 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
Description: Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
Study NCT01820247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enteral nutrition
Study NCT01820247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides
Study NCT01475903 — intervention group
Intervention type: PROCEDURE
Intervention: Longitudinal sleeve gastrectomy
Description: The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
Study NCT04292067 — intervention group
Intervention type: BIOLOGICAL
Intervention: Faecal sampling
Description: Faecal sampling at baseline
Study NCT03160040 — intervention group
Intervention type: DRUG
Intervention: Minocycline IV
Description: This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
Study NCT04086810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Description: Once daily oral administration
Study NCT02269839 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
Study NCT02269839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
Study NCT02438189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemia Minimization Algorithm
Description: The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
Study NCT02567383 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks
Study NCT02567383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperthermia; Thermotron RF-8
Description: 40 minutes within 2hr after irradiation
Study NCT02567383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20mg/m2 per week for 6 weekly cycles before radiotherapy
Study NCT02567383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 10-12mg/m2 per week for 6 weekly cycles before radiotherapy
Study NCT02732808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulation stimulation
Description: Double stimulation in 2 phases:~Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.~Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection.
Study NCT00543114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
Study NCT00543114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
Study NCT00543114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given intravenously on Day 1 of each 28 day cycle
Study NCT04634188 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin
Description: Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically
Study NCT02143219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatine
Description: Oxaliplatine : 85mg/m², 2-hours IV infusion (D1),
Study NCT02143219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Folinic acid
Description: Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),
Study NCT03766477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pittsburgh Sleep Quality Index (IQSP) and Johansson
Description: All participants will to answer the Pittsburgh Sleep Quality Index (IQSP) and Johansson questionnaires before polysomnography examination and use of APP.
Study NCT03766477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Smartphone APP
Description: All study participants will use a smartphone application (APP), which will be made available by the researchers, at the same time as the polysomnography exam.
Study NCT02143219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts~* Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max.~* Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance.
Study NCT02143219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU
Description: 5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion:~* If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one~* If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course.
Study NCT05558397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional Group (Epidural morphine)
Description: Implantation of an epidural catheter for administration of morphine and ropvacaine